Common Contracts
3 similar Note Purchase Agreement contracts by OptiNose, Inc.
ContractNote Purchase Agreement • May 5th, 2020 • Delaware
EX-10.19 3 optinose_athyriumxnotepurc.htm EXHIBIT 10.19 Execution Version NEITHER THIS NOTE PURCHASE AGREEMENT NOR THE NOTES ISSUED HEREUNDER HAVE BEEN REGISTERED PURSUANT TO THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR QUALIFIED PURSUANT TO ANY APPLICABLE STATE SECURITIES LAW. THE NOTES ISSUED UNDER THIS NOTE PURCHASE AGREEMENT MAY BE RESOLD ONLY IF REGISTERED PURSUANT TO THE PROVISIONS OF THE SECURITIES ACT AND QUALIFIED PURSUANT TO APPLICABLE STATE SECURITIES LAWS OR IF AN EXEMPTION FROM SUCH REGISTRATION AND QUALIFICATION IS AVAILABLE, EXCEPT UNDER CIRCUMSTANCES WHERE NEITHER SUCH REGISTRATION, QUALIFICATION NOR EXEMPTION IS REQUIRED BY LAW. NOTE PURCHASE AGREEMENT Dated as of December 29, 2017 among OPTINOSE AS and OPTINOSE US, INC., as the Issuers, OPTINOSE, INC., as Parent and a Guarantor The other Guarantors from time to time party hereto The Purchasers from time to time party hereto and ATHYRIUM OPPORTUNITIES III ACQUISITIO
NOTE PURCHASE AGREEMENT Dated as of December 29, 2017 among OPTINOSE AS and OPTINOSE US, INC., as the Issuers, OPTINOSE, INC., as Parent and a Guarantor The other Guarantors from time to time party heretoNote Purchase Agreement • March 13th, 2018 • OptiNose, Inc. • Pharmaceutical preparations • New York
This NOTE PURCHASE AGREEMENT is entered into as of December 29, 2017 among OPTINOSE AS, a Norwegian private limited liability company with Norwegian business registration number 982 483 131 (the “Norwegian Issuer”), OPTINOSE US, INC., a Delaware corporation (the “US Issuer”; together with the Norwegian Issuer, the “Issuers” and each, an “Issuer”), OPTINOSE, INC., a Delaware corporation (“Parent”), OPTINOSE UK LIMITED, a limited liability company formed under the laws of England and Wales (“OptiNose UK”), the other Guarantors (defined herein) from time to time party hereto, the Purchasers (defined herein) from time to time party hereto and ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as Collateral Agent.
NOTE PURCHASE AGREEMENT Dated as of December 29, 2017 among OPTINOSE AS and OPTINOSE US, INC., as the Issuers, OPTINOSE, INC., as Parent and a Guarantor The other Guarantors from time to time party heretoNote Purchase Agreement • January 2nd, 2018 • OptiNose, Inc. • Pharmaceutical preparations • New York
This NOTE PURCHASE AGREEMENT is entered into as of December 29, 2017 among OPTINOSE AS, a Norwegian private limited liability company with Norwegian business registration number 982 483 131 (the “Norwegian Issuer”), OPTINOSE US, INC., a Delaware corporation (the “US Issuer”; together with the Norwegian Issuer, the “Issuers” and each, an “Issuer”), OPTINOSE, INC., a Delaware corporation (“Parent”), OPTINOSE UK LIMITED, a limited liability company formed under the laws of England and Wales (“OptiNose UK”), the other Guarantors (defined herein) from time to time party hereto, the Purchasers (defined herein) from time to time party hereto and ATHYRIUM OPPORTUNITIES III ACQUISITION LP, as Collateral Agent.
